van Rhee A M, Siddiqi S M, Melman N, Shi D, Padgett W L, Daly J W, Jacobson K A
Molecular Recognition Section, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, USA.
J Med Chem. 1996 Jan 19;39(2):398-406. doi: 10.1021/jm9504823.
A novel class of non-nitrogen-containing heterocycles, the tetrahydrobenzothiophenones, was found to bind to adenosine receptors as antagonists in the micromolar range. Affinity was determined in radioligand-binding assays at rat brain A1 and A2a receptors. A structure-activity analysis indicated that a 3-thioether group is favored and affinity at A2a, but not at A1, receptors is highly dependent on this thioether substituent. A carboxylic acid-derived substituent is required at the 1-position of the thiophene ring, with esters being more potent in binding at A1 receptors than the corresponding carboxyl hydrazide or carboxylic acid derivatives. The methyl (15) and ethyl (16) esters are about equipotent at A1 but not at A2a receptors. A 4-keto group on the saturated ring is favored for receptor affinity. Dimethyl substitution at the 6-position of the saturated ring is allowed. One of the most potent derivatives was the nonselective compound ethyl 3-(benzylthio)-4-oxo-4,5,6,7-tetrahydrobenzo[c] thiophene-1-carboxylate (BTH4, 7; Figure 1), which antagonized adenosine agonist-induced inhibition of adenylyl cyclase in rat adipocyte membranes with a KB value of 1.62 +/- 0.73 microM and adenosine agonist-induced stimulation of adenylyl cyclase in pheochromocytoma cell membranes with a KB value of 9.19 +/- 0.98 microM. Displacement of radioligand binding by BTH4 (7) at cloned human A3 receptors was negligible but one slightly A3 selective compound (11, 3.9-fold over A1 and >7.5-fold over A2a) was found. A 1-methylpropyl thioether (17) was 29-fold selective for A1 and A2a receptors. BTH4 (7) alone, at 10 mg/kg, stimulated locomotor activity in mice but paradoxically acted, under certain circumstances, synergistically with an A1 selective agonist to depress locomotor activity. A pharmacophore model relating structural features of xanthine and non-xanthine adenosine antagonists to BTH4 (7) suggests a high degree of similarity in electrostatic surfaces, assuming that the thiophene ring superimposes the region of the uracil ring of xanthines.
一类新型的不含氮杂环化合物——四氢苯并噻吩酮,被发现可在微摩尔范围内作为拮抗剂与腺苷受体结合。通过放射性配体结合试验测定了其对大鼠脑A1和A2a受体的亲和力。结构活性分析表明,3-硫醚基团是有利的,且对A2a受体的亲和力高度依赖于该硫醚取代基,但对A1受体则不然。噻吩环的1位需要一个羧酸衍生的取代基,酯在与A1受体结合时比相应的羧基酰肼或羧酸衍生物更有效。甲酯(15)和乙酯(16)在A1受体上的效力相当,但在A2a受体上则不然。饱和环上的4-酮基有利于受体亲和力。饱和环的6位允许进行二甲基取代。最有效的衍生物之一是无选择性的化合物3-(苄硫基)-4-氧代-4,5,6,7-四氢苯并[c]噻吩-1-羧酸乙酯(BTH4, 7;图1),它在大鼠脂肪细胞膜中拮抗腺苷激动剂诱导的腺苷酸环化酶抑制作用,KB值为1.62±0.73 microM,在嗜铬细胞瘤细胞膜中拮抗腺苷激动剂诱导的腺苷酸环化酶刺激作用,KB值为9.19±0.98 microM。BTH4(7)对克隆的人A3受体放射性配体结合的置换作用可忽略不计,但发现了一种对A3受体有轻微选择性的化合物(11,对A1受体的选择性为3.9倍,对A2a受体的选择性大于7.5倍)。一种1-甲基丙基硫醚(17)对A1和A2a受体具有29倍的选择性。单独使用10 mg/kg的BTH4(7)可刺激小鼠的运动活性,但在某些情况下,它与A1选择性激动剂具有协同作用,反而会抑制运动活性。一个将黄嘌呤和非黄嘌呤腺苷拮抗剂的结构特征与BTH4(7)相关联的药效团模型表明,假设噻吩环与黄嘌呤的尿嘧啶环区域重叠,那么静电表面具有高度相似性。